We employ a differentiated &
de-risked investment strategy creating a portfolio targeting all causes of aging.

A science based investing approach focusing on:

3-5 Years
to Exit

Growth Stage
(Series B+)

Platform Tech
(Multiple Assets)

Our investment focus areas

Gene Therapies
& Editing

Cell Therapies
& Regenerative Medicine

AI Drug Discovery
& Early Diagnostics

AI-Powered Medtech
& Biosensing

Portfolio Examples

Portfolio Examples

Our deep due diligence is rooted in the science of aging and we have extended the hallmarks of aging concept into our internal model.

We are one of the few funds investing in late-stage longevity technology.

We bring a science-first approach to investing in companies building platform technologies that target biological aging as the root of disease. We back highly experienced teams, and join rounds with the largest VCs, big pharma, and big tech co-investors.

Our goal is to find and fund seasoned biotech executives who are at the forefront of advancing longevity and biotechnologies.